Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women
Yıl: 2021 Cilt: 27 Sayı: 2 Sayfa Aralığı: 103 - 108 Metin Dili: İngilizce DOI: 10.4274/vhd.galenos.2021.2020-12-2 İndeks Tarihi: 04-06-2022
Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women
Öz: Objectives: Vertical transmission of hepatitis B virus, hepatitis
C virus, (HBV, HCV) and human immunodeficiency viruses (HIV)
infections is an important public health problem. The aim of this
study was to determine the rates of hepatitis B, anti-HCV and antiHIV seropositivities in pregnant women in a city and to evaluate the
infections in terms of perinatal outcomes.
Materials and Methods: In this retrospective study, 8,464 patients
who gave birth in obstetrics and gynecology clinic were recorded.
Seropositivity rates of pregnant women were investigated according
to the results of hepatitis B surface antigen (HBsAg), HCV antibody
and anti-HIV antibody. The rates were determined according to
years and perinatal results and statistical comparison was made.
Results: HBsAg seropositivity in pregnant women included in the
study was 2.8 % (n=55) in 2015, 2.2% (n=52) in 2016, 2.3% (n=47)
in 2017 and 2.2% (n=49) in 2018. The 4 year average was found
to be 2.3% (n=203). There was no significant difference between
the years (p>0.05). Among all our patients, 4-year mean anti-HCV
seropositivity was 0.57% (n=49) and there was no difference
between years (p>0.05). Anti-HIV seropositivity was found to
be 0.09% on average, and there was no statistically significant
difference over the years (p>0.05).
Conclusion: Since hepatitis B, which is a preventable viral disease,
has a risk of transmission during delivery and if it is transmitted to the
fetus, it may lead to fatal complications at later ages, it is necessary
to screen all pregnant women in terms of HBsAg seropositivity and
to include it in an antepartum planning program to protect and treat
newborns from infection. Although the transmission rate of HCV is
low in the society, considering its clinical course, screening of HCV together with HIV in risky groups and pregnant women antibody
positivity is considered important for the health of the society and
newborns.
Anahtar Kelime: Gebe Kadınlarda HBsAg, Anti-HCV, Anti-HIV Seroprevalansının ve Perinatal SonuçlarınDeğerlendirilmesi
Öz: Amaç: Hepatit B virüsü, hepatitis C virüsü (HBV, HCV) ve insan immün
yetmezlik virüsleri (HIV) enfeksiyonlarının dikey bulaşması önemli bir
halk sağlığı problemidir. Bu çalışmadaki amaç bir ildeki gebelerde
hepatit B, anti-HCV ve anti-HIV seropozitiflik oranlarını belirlemek ve
enfeksiyonları perinatal sonuçlar açısından değerlendirmektir.
Gereç ve Yöntemler: Bu retrospektif çalışmada kadın hastalıkları ve
doğum kliniğinde doğumu gerçekleştirilmiş 8,464 hasta kayıt altına
alınmıştır. Gebelerde seropozitiflik oranları, hepatit B yüzey antijeni
(HBsAg), HCV antikoru ve tespit edilen anti-HIV antikoru sonuçlarına
göre araştırıldı. Yıllara göre ve perinatal sonuçlara göre oranlar
belirlenip istatistiki karşılaştırma yapıldı.
Bulgular: Çalışmaya alınan gebelerde HBsAg seropozitifliği 2015
yılında %2,8 (n=55), 2016 yılında %2,2 (n=52), 2017 yılında %2,3
(n=47) ve 2018 yılında ise %2,2 (n=49) bulunmuş olup 4 yıllık
ortalaması %2,3 (n=203) olarak hesaplanmıştır. Yıllar arasında
anlamlı bir farklılık gözlenmemiştir (p>0,05). Tüm hastalarımız içinde
dört yıllık ortalama anti-HCV seropozitifliği %0,57 (n=49) olup yıllar
arasında fark bulunmadı (p>0,05). Anti-HIV seropozitifliği ortalama
olarak %0,09 olarak saptanmış olup yıllara göre istatistiki anlamda
bir farklılık izlenmemiştir (p>0,05).
Sonuç: Önlenebilir bir viral hastalık olan hepatit B’nin doğum
esnasında bulaş riski olduğundan ve fetusta bulaş olursa ilerleyen
yaşlarda ölümcül komplikasyonlara yol açabileceğinden tüm
gebelerin HBsAg seropozitifliği açısından taranması ve bunun bir
antepartum planlama programına dahil edilmesi yenidoğanların
enfeksiyondan korunması ve tedavi edilmesi için gereklidir. HCV’nin
toplumda bulaş oranı düşük bir düzeyde olmasına karşın klinik seyri dikkate alındığında riskli gruplarda ve gebelerde HIV ile birlikte
taranması toplum ve yenidoğan bebeklerin sağlığı için önemli
görülmektedir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Curry MP, Chopra S. Acute viral hepatitis. Principles and practice of infectious diseases. Philadelphia: Elsevier Churchill Livingstone; 2005; pp. 1426-1441.
- 2. Aygen B. Hepatit A Virusu. Ed: Willke Topçu A, Söyletir G, Doğanay M. Infectious Diseases and Microbiology Volume II. Istanbul; Nobel Medical Bookstores, 2002; pp. 1340-9.
- 3. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occupational Med 2011;61:531-540.
- 4. Mıstık R, Balık İ. Epidemiological analysis of viral hepatitis in Turkey. Viral Hepat J 2003;1:10-55.
- 5. Ghendon Y. Perinatal transmission of hepatitis B virus in highincidence countries. J Virol Methods 1987;17:69-79.
- 6. Taşyaran MA. Epidemiology of HBV Infection. Tekeli E, Balık İ, editors. 1st Edition. Istanbul: Character Color A.Ş; 2003; pp. 121- 128.
- 7. Wasmuth JC. Hepatitis B-Epidemiology, transmission and natural history. In: Mauss S, Berg T, Rockstroh J, SarrazinC, Wedemeyer H, editors. Hepatology. Dusseldorf: Flying Publisher; 2009; pp. 37-48.
- 8. Turhan NÖ, Kaygusuz İÇ, Pekel A. Assisted Reproduction Techniques in HIV Positive Couples: Review. Turkiye Klinikleri J Gynecol Obst 2007;117-125
- 9. Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period-are they opportunities for treatment? Viral Hepat J. 2011;18:229-236.
- 10. LeFevre ML. U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:58-66.
- 11. Tosun S. The changing epidemiology of viral hepatitis in our country. Ankem J 2013;27:128-134.
- 12. Kartal B. Knowledge Levels and Practices on Hepatitis B of Mothers of 0-6 Age Group Children Admitted to Nevsehir State Hospital Pediatrics Service, (Master Thesis), Erciyes University Institute of Health Sciences, Kayseri; 2003.
- 13. Yi P, Chen R, Huang Y, Zhou RR, Fan XG. Management of motherto-child transmission of hepatitis B virus: propositions and challenges. J Clin Virol 2016;77:32-39.
- 14. Petrova M, Kamburov V. Breastfeeding and chronic HBV infection: clinical and social implications. World J Gastroenterol 2010;16:5042.
- 15. Petersen J. HBV treatment and pregnancy. J Hepatol 2011;55:117.
- 16. Kölgelier S, Güler D, Demiraslan H. HBsAg and Anti-HCV prevalence in pregnant women in Adıyaman. Dicle Med J 2009;36:191-194
- 17. Polat S, Camurdan AD, Aksakal N, Agladioglu S, Beyazova, U, Sahin F, Er A. Evaluation of perinatal and intrafamilial hepatitis B prevention programmes in a well child clinic: 9-year follow-up study in Turkey. Trans R Soc Trop Med Hyg 2011;105:220-225.
- 18. Madendağ Y, Çöl Madendağ D, Çelen Ş, Ünlü S, Danşman N. All obstetric and gynecological patients in our hospital applicant Hepatitis B, Hepatitis C and HIV Seroprevalence. Turkey Clin J Gynecol 2007;17: 442-446.
- 19. Tosun S. Meta-analysis of publications epidemiology of viral hepatitis B in Turkey. In: Tabak F, Tosun S, editors. Viral Hepatitis 2013. 1st Edition Istanbul: Medikal Sağlık ve Yayıncılık; 2013; pp. 25-80.
- 20. Kölgelier S, Demir LS, Demir NA, Özçimen S, Tabak S. Seropositivity of HBsAg and anti-HCV in Pregnant Women in Adiyaman. Viral Hepat J 2012 18:98-101.
- 21. Furuncuoglu Y, Bolukbas FF, Bolukbas C, Torun P. Changes in the prevalence of HBV infection in pregnant women in Turkey between 1995 and 2015: a 20-year evaluation. Postgrad Med J 2016;92:510-513.
- 22. Tanrıverdi EÇ, Özkurt Z, Kadıoğlu BG, Alay H, Çalıkoğlu O, Koca Ö, Kamalak Z. Seroprevalence of hepatitis B, hepatitis C, and HIV in pregnant women from Eastern Turkey. Turk J Gastroenterol 2019;30:260-265.
- 23. Bilgiç A, Özaçar T. Hepatitis B Virus Infection Diseases and Microbiology. Istanbul, Nobel Medical Bookstores; 2002; pp. 1350-1370.
- 24. Collenberg E, Ouedraogo T, Ganamé J, Fickenscher H, KynastWolf G, Becher H, Tebit D. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: a comparative analysis. J Med Virol 2006;78:683- 692.
- 25. Prasad LR, Spicher VM, Kammerlander R. Hepatitis C in a sample of pregnant women in Switzerland: seroprevalence and sociodemografic factors. Swiss Med Wkly 2007;137:27-32.
- 26. Gönen I. HBV and HCV prevalence in pregnant women in rural areas. J Viral Hepat 2011;17:66-68.
- 27. Özlü T, Taş T, Mengeloğlu FZ, Koçoğlu E, Dönmez ME. The prevalence of HBsAg, anti-HCV and anti-HIV in pregnant women and / or women with gynecological disease in a tertiary hospital. J Clin Exp Invest 2013;4.
- 28. Mıstık R. The epidemiology of hepatitis C virus infection. In: Tabak F, Tosun S, editors. Viral Hepatitis, 1st Edition Istanbul: Medical Health and Publishing; 2013; pp. 83-112.
- 29. Rimawi BH, Haddad L, Badell ML, Chakraborty R. Management of HIV infection during pregnancy in the United States: updated evidence-based recommendations and future potential practices. Infect Dis Obstet Gynecol 2016; 2016:7594306.
- 30. Jamieson DJ, Read JS, Kourtis AP, Durant TM, Lampe MA, Dominguez KL. Cesarean delivery for HIV-infected women: recommendations and controversies. Am J Obstet Gynecol 2007;(Suppl3)197:S96-100.
- 31. Balık G, Üstüner I, Kağıtcı M, Ural ÜM, Tekin YB, Şentürk Ş, Şahin FK. HBsAg, AntiHBs and Anti-HCV seroprevalence in pregnant women living in the Rize region. Dicle Med J 2013;40:254-257.
- 32. İnci A, Okay M, Güven D. HBsAg, Anti-HBs, Anti-HCV and AntiHIV seroprevalence in patients admitted to Artvin state hospital. Viral Hepat J2014;19:41-44.
- 33. Asan A, Akbulut A, Saçar S, Turgut H. Evaluation of HBsAg and Anti-HCV seroprevalence in people applying to Tunceli State Hospital. J Viral Hepat 2011;17:52-56.
- 34. Yıldız B, Bucaktepe PGE, Yıldız İ, Kara İH. Relationships between HBsAg and AntiHCV Seropositivity Rates and Risk Factors of Pregnant Women Hospitalized in Gynecology and Obstetrics Clinic and Other Patients. Konuralp Med J 4:27-34
APA | uckan K, Çeleğen İ, uçkan T (2021). Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women. , 103 - 108. 10.4274/vhd.galenos.2021.2020-12-2 |
Chicago | uckan Kazım,Çeleğen İzzet,uçkan Taner Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women. (2021): 103 - 108. 10.4274/vhd.galenos.2021.2020-12-2 |
MLA | uckan Kazım,Çeleğen İzzet,uçkan Taner Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women. , 2021, ss.103 - 108. 10.4274/vhd.galenos.2021.2020-12-2 |
AMA | uckan K,Çeleğen İ,uçkan T Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women. . 2021; 103 - 108. 10.4274/vhd.galenos.2021.2020-12-2 |
Vancouver | uckan K,Çeleğen İ,uçkan T Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women. . 2021; 103 - 108. 10.4274/vhd.galenos.2021.2020-12-2 |
IEEE | uckan K,Çeleğen İ,uçkan T "Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women." , ss.103 - 108, 2021. 10.4274/vhd.galenos.2021.2020-12-2 |
ISNAD | uckan, Kazım vd. "Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women". (2021), 103-108. https://doi.org/10.4274/vhd.galenos.2021.2020-12-2 |
APA | uckan K, Çeleğen İ, uçkan T (2021). Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women. Viral Hepatitis Journal, 27(2), 103 - 108. 10.4274/vhd.galenos.2021.2020-12-2 |
Chicago | uckan Kazım,Çeleğen İzzet,uçkan Taner Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women. Viral Hepatitis Journal 27, no.2 (2021): 103 - 108. 10.4274/vhd.galenos.2021.2020-12-2 |
MLA | uckan Kazım,Çeleğen İzzet,uçkan Taner Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women. Viral Hepatitis Journal, vol.27, no.2, 2021, ss.103 - 108. 10.4274/vhd.galenos.2021.2020-12-2 |
AMA | uckan K,Çeleğen İ,uçkan T Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women. Viral Hepatitis Journal. 2021; 27(2): 103 - 108. 10.4274/vhd.galenos.2021.2020-12-2 |
Vancouver | uckan K,Çeleğen İ,uçkan T Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women. Viral Hepatitis Journal. 2021; 27(2): 103 - 108. 10.4274/vhd.galenos.2021.2020-12-2 |
IEEE | uckan K,Çeleğen İ,uçkan T "Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women." Viral Hepatitis Journal, 27, ss.103 - 108, 2021. 10.4274/vhd.galenos.2021.2020-12-2 |
ISNAD | uckan, Kazım vd. "Evaluation of HBsAg, Anti-HCV, Anti-HIV Seroprevalence and Perinatal Outcomes in Pregnant Women". Viral Hepatitis Journal 27/2 (2021), 103-108. https://doi.org/10.4274/vhd.galenos.2021.2020-12-2 |